HomeCompareANPCY vs EPRT

ANPCY vs EPRT: Dividend Comparison 2026

ANPCY yields 2985.07% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANPCY wins by $433539968075.05M in total portfolio value
10 years
ANPCY
ANPCY
● Live price
2985.07%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$433539968075.12M
Annual income
$406,736,225,519,142,500.00
Full ANPCY calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ANPCY vs EPRT

📍 ANPCY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANPCYEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANPCY + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANPCY pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANPCY
Annual income on $10K today (after 15% tax)
$253,731.34/yr
After 10yr DRIP, annual income (after tax)
$345,725,791,691,271,200.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ANPCY beats the other by $345,725,791,691,260,200.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANPCY + EPRT for your $10,000?

ANPCY: 50%EPRT: 50%
100% EPRT50/50100% ANPCY
Portfolio after 10yr
$216769984037.59M
Annual income
$203,368,112,759,577,700.00/yr
Blended yield
93.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ANPCY
No analyst data
Altman Z
-11.9
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANPCY buys
0
EPRT buys
0
No recent congressional trades found for ANPCY or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANPCYEPRT
Forward yield2985.07%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$433539968075.12M$63.4K
Annual income after 10y$406,736,225,519,142,500.00$12,840.73
Total dividends collected$431686299125.80M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ANPCY vs EPRT ($10,000, DRIP)

YearANPCY PortfolioANPCY Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$309,207$298,507.46$11,205$505.18+$298.0KANPCY
2$8,957,089$8,626,236.93$12,672$682.46+$8.94MANPCY
3$243,120,454$233,536,368.64$14,490$930.48+$243.11MANPCY
4$6,184,279,490$5,924,140,604.30$16,786$1,282.69+$6184.26MANPCY
5$147,451,722,719$140,834,543,664.57$19,753$1,791.56+$147451.70MANPCY
6$3,296,013,356,428$3,138,240,013,119.13$23,677$2,541.64+$3296013.33MANPCY
7$69,087,118,460,072$65,560,384,168,694.19$29,008$3,672.99+$69087118.43MANPCY
8$1,358,221,282,082,432$1,284,298,065,330,154.50$36,463$5,425.08+$1358221282.05MANPCY
9$25,050,226,687,827,436$23,596,929,915,999,230.00$47,238$8,221.57+$25050226687.78MANPCY
10$433,539,968,075,117,900$406,736,225,519,142,500.00$63,385$12,840.73+$433539968075.05MANPCY

ANPCY vs EPRT: Complete Analysis 2026

ANPCYStock

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Full ANPCY Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ANPCY vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANPCY vs SCHDANPCY vs JEPIANPCY vs OANPCY vs KOANPCY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.